NVAX

#2253
Novavax Inc
8.19 USD
+0.99%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
8.14
8.22
년간 변동
5.80
11.97
일일 변동
+0.99%
월간 변동
-21.02%
6달 변화
-8.39%
년간 변동율
+28.17%
이전 종가
8.11
Open
8.20
Bid
Ask
Low
8.14
High
8.22
양
381
Open full chart

Financials

Overview 성명 Statistics Dividends
Quarterly Annual
  • Market Capitalization 1.33 B
  • Employee 749
  • Founded 1987
  • CEO John C. Jacobs
  • Website www.novavax.com
  • Headquarter Delaware, United States
  • FIGI BBG000NVSBL7
  • Industry Technology
총매출
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
2.6
Price to sales ratio
1.04

Novavax Inc

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

뉴스